AstraZeneca seeks FDA approval for COVID-19 antibody treatment

Published by
New York Daily News

AstraZeneca has asked the Food and Drug Administration to approve its COVID-19 antibody treatment that would act as a long-acting drug mainly for those with compromised immune systems. The drugmaker — which was among the first to create a COVID-19 vaccine — said its antibody treatment, AZD7442, is a first of its kind therapy that utilizes long-acting antibody protection. “First and foremost we want to protect those vulnerable populations that haven’t been adequately protected by the vaccine,” said Menelas Pangaloa, AstraZeneca’s head of research and development. “But ultimately it will be up t…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *